US5057519A
Expired / Lapsed
US
⏱️ 0.0 years remaining
5-HT3 antagonists: use in reducing opiate tolerance
Assignee: Bristol Myers Squibb Co
•
Filing: 1990-06-11
•
Granted: 1991-10-15
•
Expires: 2010-06-11
Abstract
Abstract The use of 5-HT3 antagonists and their pharmaceutically acceptable salts in reducing tolerance to opiates in particular morphine.
Inventors
- 👤 Stacy N. Suberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 13:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
44 words
A method for significantly delaying the onset of opiate tolerance, which method comprises concomitantly administering an opiate with a therapeutically effective amount of a benzamide-type 5-HT 3 antagonist, or a pharmaceutically effective acid addition salt thereof, to a patient in need of such treatment.
Claim 2
Independent Claim
44 words
A method for significantly delaying the onset of opiate tolerance, which method comprises concomitantly administering an opiate with a therapeutically effective amount of a benzamide-type 5-HT 3 antagonist, or a pharmaceutically effective acid addition salt thereof, to a patient in need of such treatment.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the opiate is morphine.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein the benzamide-type 5-HT 3 antagonist is zacopride.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein the benzamide-type 5-HT 3 antagonist is batanopride.
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein the benzamide -type 5-HT 3 antagonist is BMY 33462.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein the dosage is about 0.25 to about 250 mg/day.
Claim 8
Dependent Claim
39 words
The method of claim 1 wherein the amount of said benzamide-type 5-HT 3 antagonist is sufficient to inhibit the development of tolerance to and physical dependence on the opiate without substantial alteration of the analgesic properties of the opiate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-10-14 | 1995-04-15 | 1995-10-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-10-14 | 1999-04-15 | 1999-10-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-10-14 | 2003-04-15 | 2003-10-15 | $7700.00 | Window Closed / Lapsed |